Mesoblast (MESO) Form 6-K furnishes ASX new issue and quotation filings
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to two Australian Securities Exchange filings. The report furnishes an April 7, 2026 Appendix 3B new issue announcement and an April 8, 2026 Appendix 2A application for quotation of securities as exhibits.
Positive
- None.
Negative
- None.
Key Terms
Form 6-K, Foreign Private Issuer, Appendix 3B, Appendix 2A, +1 more
5 terms
Form 6-K regulatory
"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Foreign Private Issuer regulatory
"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Appendix 3B financial
"a new issue announcement, proposed issue of securities (Appendix 3B)"
Appendix 2A financial
"a new issue announcement, application for quotation of securities (Appendix 2A)"
application for quotation of securities financial
"a new issue announcement, application for quotation of securities (Appendix 2A)"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of April 2026
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
(Jurisdiction of incorporation or organization)
Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐
INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On April 7, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, proposed issue of securities (Appendix 3B) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
On April 8, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, application for quotation of securities (Appendix 2A) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.
Mesoblast Limited | ||||||||||||||
/s/ Niva Sivakumar | ||||||||||||||
| Niva Sivakumar | ||||||||||||||
| Company Secretary | ||||||||||||||
Dated: April 8, 2026
INDEX TO EXHIBITS
| Item | ||||||||
99.1 | Appendix 3B of Mesoblast Ltd, dated April 7, 2026 | |||||||
99.2 | Appendix 2A of Mesoblast Ltd, dated April 8, 2026 | |||||||
Exhibit 99.1
Exhibit 99.2
FAQ
What does Mesoblast Limited's (MESO) April 2026 Form 6-K cover?
The Form 6-K from Mesoblast Limited provides copies of two Australian Securities Exchange documents. These are an Appendix 3B new issue announcement and an Appendix 2A application for quotation of securities, both incorporated in the report as exhibits for U.S. investors.
Which ASX documents are attached to Mesoblast (MESO)'s Form 6-K?
The filing attaches Appendix 3B dated April 7, 2026 and Appendix 2A dated April 8, 2026. Appendix 3B is a new issue announcement, while Appendix 2A is an application for quotation of securities on the Australian Securities Exchange.
Why did Mesoblast Limited (MESO) file this Form 6-K with the SEC?
Mesoblast filed the Form 6-K to furnish its Australian Securities Exchange new issue announcement and application for quotation of securities. This ensures U.S. market participants can access the same material information through the SEC’s reporting system via attached exhibits.
What is Appendix 3B referenced in Mesoblast (MESO)'s Form 6-K?
Appendix 3B in the filing is described as a "new issue announcement, proposed issue of securities" lodged with the Australian Securities Exchange on April 7, 2026. It is attached to the Form 6-K as Exhibit 99.1 and incorporated by reference.
What is Appendix 2A in Mesoblast Limited (MESO)'s April 2026 Form 6-K?
Appendix 2A is an "application for quotation of securities" filed with the Australian Securities Exchange on April 8, 2026. It appears in the Form 6-K as Exhibit 99.2, allowing U.S. investors to review the same document through SEC channels.
Does Mesoblast (MESO) indicate its reporting status in this Form 6-K?
Yes. The document states Mesoblast Limited is a foreign private issuer and indicates that it files or will file annual reports under cover of Form 20-F, aligning its ongoing SEC reporting framework with that form rather than Form 40-F.